Wong Daniel Ho Tak, Hung Jennifer Chien Hui, Li Kenneth Kai Wang
Department of Ophthalmology, United Christian Hospital, Hospital Authority, 130 Hip Wo Street, Kwun Tong, Hong Kong SAR, China.
Department of Ophthalmology, Tseung Kwan O Hospital, Hospital Authority, 2 Po Ning Lane, Tseung Kwan O, Hong Kong SAR, China.
Int Ophthalmol. 2025 May 5;45(1):176. doi: 10.1007/s10792-025-03518-1.
Management of endogenous endophthalmitis (EE) is challenging. Klebsiella EE, in particular, carries a guarded prognosis and poor visual outcome. We aimed to test the hypothesis that a certain group of Klebsiella EE would carry a better prognosis when presenting with specific signs, compared to the worse-performing group when treated with initial systemic and intravitreal therapy.
A retrospective cohort study was conducted across two local tertiary hospitals to review all cases of Klebsiella EE from January 2013 to December 2022. Anatomical success was defined by retention of the globe, without intractable retinal detachment or phthisis bulbi. Functional success was defined as achieving a visual acuity of better than 1.3 logMAR.
A total of 56 proven cases of EE were identified. 31 subjects (55.4%) had Klebsiella EE. Of those, 31 eyes of 21 subjects met the inclusion criteria. 4 subjects were unconscious or cognitively impaired at initial presentation. The factors that predict a higher chance of successful treatment with systemic antibiotics and intravitreal antibiotics only, in the Klebsiella EE group, were a better visual acuity at presentation, lack of conjunctival injection, absence of corneal edema, hypopyon, panophthalmitis, and the presence of a fundal view (p < 0.02). The probability of overall treatment success was greater than 50% if the initial visual acuity was better than or close to finger counting at one meter (p = 0.006).
Universal screening of patients with Klebsiella infection and the identification of earlier EE presentation with these prognostic factors that predict a positive or less severe outcome are crucial for the prompt initiation of treatment within this narrow therapeutic window.
内源性眼内炎(EE)的治疗具有挑战性。尤其是肺炎克雷伯菌性EE,其预后不佳,视力恢复差。我们旨在验证这一假设:与接受初始全身及玻璃体腔内治疗时预后较差的组相比,某一组肺炎克雷伯菌性EE在出现特定体征时预后会更好。
在两家当地三级医院开展了一项回顾性队列研究,以回顾2013年1月至2022年12月期间所有肺炎克雷伯菌性EE病例。解剖学成功定义为眼球保留,无难治性视网膜脱离或眼球痨。功能成功定义为视力达到优于1.3 logMAR。
共确定了56例经证实的EE病例。31名受试者(55.4%)患有肺炎克雷伯菌性EE。其中,21名受试者的31只眼符合纳入标准。4名受试者在初次就诊时无意识或认知受损。在肺炎克雷伯菌性EE组中,仅用全身抗生素和玻璃体腔内抗生素治疗成功可能性较高的因素包括就诊时视力较好、无结膜充血、无角膜水肿、无前房积脓、无全眼球炎以及眼底可见(p < 0.02)。如果初始视力优于或接近1米指数,则总体治疗成功的概率大于50%(p = 0.006)。
对肺炎克雷伯菌感染患者进行普遍筛查,并识别出具有这些预测良好或较轻预后的预后因素的早期EE表现,对于在这个狭窄的治疗窗口期内及时开始治疗至关重要。